Do analysts prefer MDP or WEED?

Canopy Growth has a consensus price target of C$1.88, indicating a potential upside of 34.89%. Given Canopy Growth's stronger consensus rating and higher possible upside, analysts clearly believe Canopy Growth is more favorable than Medexus Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Medexus Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Canopy Growth 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67

Does the media favor MDP or WEED?

In the previous week, Medexus Pharmaceuticals and Medexus Pharmaceuticals both had 2 articles in the media. Medexus Pharmaceuticals' average media sentiment score of 1.23 beat Canopy Growth's score of 0.78 indicating that Medexus Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Medexus Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Canopy Growth 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend FRX or MDP?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Fennec Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 4.00 Medexus Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Does the media refer more to FRX or MDP?

In the previous week, Medexus Pharmaceuticals had 1 more articles in the media than Fennec Pharmaceuticals. MarketBeat recorded 2 mentions for Medexus Pharmaceuticals and 1 mentions for Fennec Pharmaceuticals. Medexus Pharmaceuticals' average media sentiment score of 1.23 beat Fennec Pharmaceuticals' score of 0.00 indicating that Medexus Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Fennec Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Medexus Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to CPH or MDP?

In the previous week, Cipher Pharmaceuticals and Cipher Pharmaceuticals both had 2 articles in the media. Medexus Pharmaceuticals' average media sentiment score of 1.23 beat Cipher Pharmaceuticals' score of 1.23 indicating that Medexus Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cipher Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Medexus Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Medexus Pharmaceuticals (MDP) Competitors

C$5.31 -0.14 (-2.57%)

As of 01:11 PM Eastern

Compare

MDP vs. WEED, FRX, CPH, VGW, and VBV

Should you buy Medexus Pharmaceuticals stock or one of its competitors? Medexus Pharmaceuticals's main competitors and comparable companies include Canopy Growth (WEED), Fennec Pharmaceuticals (FRX), Cipher Pharmaceuticals (CPH), Valens GroWorks (VGW), and VBI Vaccines (VBV). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Medexus Pharmaceuticals compare to Canopy Growth?

Medexus Pharmaceuticals (TSE:MDP) and Canopy Growth (TSE:WEED) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, valuation, media sentiment, dividends, risk, profitability and institutional ownership.

Canopy Growth has a consensus price target of C$1.88, indicating a potential upside of 34.89%. Given Canopy Growth's stronger consensus rating and higher possible upside, analysts clearly believe Canopy Growth is more favorable than Medexus Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Medexus Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Canopy Growth	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67

In the previous week, Medexus Pharmaceuticals and Medexus Pharmaceuticals both had 2 articles in the media. Medexus Pharmaceuticals' average media sentiment score of 1.23 beat Canopy Growth's score of 0.78 indicating that Medexus Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Medexus Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Canopy Growth	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Medexus Pharmaceuticals has a net margin of -2.32% compared to Canopy Growth's net margin of -73.95%. Medexus Pharmaceuticals' return on equity of -4.72% beat Canopy Growth's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Medexus Pharmaceuticals	-2.32%	-4.72%	4.89%
Canopy Growth	-73.95%	-29.85%	-3.83%

3.5% of Medexus Pharmaceuticals shares are owned by institutional investors. Comparatively, 4.1% of Canopy Growth shares are owned by institutional investors. 9.1% of Medexus Pharmaceuticals shares are owned by company insiders. Comparatively, 0.2% of Canopy Growth shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Medexus Pharmaceuticals has higher earnings, but lower revenue than Canopy Growth. Medexus Pharmaceuticals is trading at a lower price-to-earnings ratio than Canopy Growth, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Medexus Pharmaceuticals	C$103.30M	1.63	C$3.26M	-C$0.07	N/A
Canopy Growth	C$293.63M	2.00	-C$1.05B	-C$0.67	N/A

Medexus Pharmaceuticals has a beta of 0.202042, meaning that its share price is 80% less volatile than the broader market. Comparatively, Canopy Growth has a beta of 1.382001, meaning that its share price is 38% more volatile than the broader market.

Summary

Canopy Growth beats Medexus Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

How does Medexus Pharmaceuticals compare to Fennec Pharmaceuticals?

Fennec Pharmaceuticals (TSE:FRX) and Medexus Pharmaceuticals (TSE:MDP) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, profitability, dividends, risk, earnings, institutional ownership, analyst recommendations and valuation.

14.5% of Fennec Pharmaceuticals shares are owned by institutional investors. Comparatively, 3.5% of Medexus Pharmaceuticals shares are owned by institutional investors. 16.2% of Fennec Pharmaceuticals shares are owned by insiders. Comparatively, 9.1% of Medexus Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Medexus Pharmaceuticals has a net margin of -2.32% compared to Fennec Pharmaceuticals' net margin of -6.21%. Medexus Pharmaceuticals' return on equity of -4.72% beat Fennec Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fennec Pharmaceuticals	-6.21%	-13.34%	8.88%
Medexus Pharmaceuticals	-2.32%	-4.72%	4.89%

Fennec Pharmaceuticals has a beta of 3.548856, indicating that its stock price is 255% more volatile than the broader market. Comparatively, Medexus Pharmaceuticals has a beta of 0.202042, indicating that its stock price is 80% less volatile than the broader market.

In the previous week, Medexus Pharmaceuticals had 1 more articles in the media than Fennec Pharmaceuticals. MarketBeat recorded 2 mentions for Medexus Pharmaceuticals and 1 mentions for Fennec Pharmaceuticals. Medexus Pharmaceuticals' average media sentiment score of 1.23 beat Fennec Pharmaceuticals' score of 0.00 indicating that Medexus Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Fennec Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Medexus Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Medexus Pharmaceuticals has higher revenue and earnings than Fennec Pharmaceuticals. Medexus Pharmaceuticals is trading at a lower price-to-earnings ratio than Fennec Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fennec Pharmaceuticals	C$51.00M	11.59	-C$800.44K	-C$0.29	N/A
Medexus Pharmaceuticals	C$103.30M	1.63	C$3.26M	-C$0.07	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fennec Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	4.00
Medexus Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Fennec Pharmaceuticals beats Medexus Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

How does Medexus Pharmaceuticals compare to Cipher Pharmaceuticals?

Cipher Pharmaceuticals (TSE:CPH) and Medexus Pharmaceuticals (TSE:MDP) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, valuation, dividends, profitability, risk, analyst recommendations, institutional ownership and media sentiment.

2.3% of Cipher Pharmaceuticals shares are owned by institutional investors. Comparatively, 3.5% of Medexus Pharmaceuticals shares are owned by institutional investors. 42.0% of Cipher Pharmaceuticals shares are owned by company insiders. Comparatively, 9.1% of Medexus Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Cipher Pharmaceuticals has a beta of 1.153789, meaning that its stock price is 15% more volatile than the broader market. Comparatively, Medexus Pharmaceuticals has a beta of 0.202042, meaning that its stock price is 80% less volatile than the broader market.

Cipher Pharmaceuticals has a net margin of 58.81% compared to Medexus Pharmaceuticals' net margin of -2.32%. Cipher Pharmaceuticals' return on equity of 22.74% beat Medexus Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cipher Pharmaceuticals	58.81%	22.74%	7.90%
Medexus Pharmaceuticals	-2.32%	-4.72%	4.89%

Cipher Pharmaceuticals has higher earnings, but lower revenue than Medexus Pharmaceuticals. Medexus Pharmaceuticals is trading at a lower price-to-earnings ratio than Cipher Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cipher Pharmaceuticals	C$50.94M	7.04	C$11.41M	C$1.19	11.87
Medexus Pharmaceuticals	C$103.30M	1.63	C$3.26M	-C$0.07	N/A

Cipher Pharmaceuticals currently has a consensus price target of C$17.00, indicating a potential upside of 20.31%. Given Cipher Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts clearly believe Cipher Pharmaceuticals is more favorable than Medexus Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cipher Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Medexus Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, Cipher Pharmaceuticals and Cipher Pharmaceuticals both had 2 articles in the media. Medexus Pharmaceuticals' average media sentiment score of 1.23 beat Cipher Pharmaceuticals' score of 1.23 indicating that Medexus Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cipher Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Medexus Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Cipher Pharmaceuticals beats Medexus Pharmaceuticals on 11 of the 14 factors compared between the two stocks.

How does Medexus Pharmaceuticals compare to Valens GroWorks?

Valens GroWorks (CVE:VGW) and Medexus Pharmaceuticals (TSE:MDP) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, institutional ownership, dividends, earnings, analyst recommendations, media sentiment and profitability.

Valens GroWorks has a net margin of 0.00% compared to Medexus Pharmaceuticals' net margin of -2.32%. Valens GroWorks' return on equity of 0.00% beat Medexus Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Valens GroWorks	N/A	N/A	N/A
Medexus Pharmaceuticals	-2.32%	-4.72%	4.89%

3.5% of Medexus Pharmaceuticals shares are held by institutional investors. 9.1% of Medexus Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Medexus Pharmaceuticals had 2 more articles in the media than Valens GroWorks. MarketBeat recorded 2 mentions for Medexus Pharmaceuticals and 0 mentions for Valens GroWorks. Medexus Pharmaceuticals' average media sentiment score of 1.23 beat Valens GroWorks' score of 0.00 indicating that Medexus Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Valens GroWorks	Neutral
Medexus Pharmaceuticals	Positive

Medexus Pharmaceuticals has higher revenue and earnings than Valens GroWorks. Medexus Pharmaceuticals is trading at a lower price-to-earnings ratio than Valens GroWorks, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Valens GroWorks	C$27.50M	13.96	-C$22.41M	-C$0.18	N/A
Medexus Pharmaceuticals	C$103.30M	1.63	C$3.26M	-C$0.07	N/A

Summary

Medexus Pharmaceuticals beats Valens GroWorks on 8 of the 12 factors compared between the two stocks.

How does Medexus Pharmaceuticals compare to VBI Vaccines?

VBI Vaccines (TSE:VBV) and Medexus Pharmaceuticals (TSE:MDP) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, earnings, dividends, profitability, institutional ownership, risk, analyst recommendations and valuation.

3.5% of Medexus Pharmaceuticals shares are owned by institutional investors. 9.1% of Medexus Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Medexus Pharmaceuticals has higher revenue and earnings than VBI Vaccines. Medexus Pharmaceuticals is trading at a lower price-to-earnings ratio than VBI Vaccines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
VBI Vaccines	C$3.36M	0.00	-C$62.16M	-C$0.97	N/A
Medexus Pharmaceuticals	C$103.30M	1.63	C$3.26M	-C$0.07	N/A

VBI Vaccines has a net margin of 0.00% compared to Medexus Pharmaceuticals' net margin of -2.32%. VBI Vaccines' return on equity of 0.00% beat Medexus Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
VBI Vaccines	N/A	N/A	N/A
Medexus Pharmaceuticals	-2.32%	-4.72%	4.89%

In the previous week, Medexus Pharmaceuticals had 2 more articles in the media than VBI Vaccines. MarketBeat recorded 2 mentions for Medexus Pharmaceuticals and 0 mentions for VBI Vaccines. Medexus Pharmaceuticals' average media sentiment score of 1.23 beat VBI Vaccines' score of 0.00 indicating that Medexus Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
VBI Vaccines	Neutral
Medexus Pharmaceuticals	Positive

Summary

Medexus Pharmaceuticals beats VBI Vaccines on 8 of the 11 factors compared between the two stocks.

Get Medexus Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MDP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MDP vs. The Competition

Export

Metric	Medexus Pharmaceuticals	Pharmaceuticals Industry	Healthcare Sector	TSE Exchange
Market Cap	C$168.12M	C$11.72B	C$6.98B	C$12.55B
Dividend Yield	N/A	2.70%	2.58%	6.20%
P/E Ratio	-75.86	781.44	269.27	30.74
Price / Sales	1.63	748.15	597.31	9.76
Price / Cash	N/A	67.45	70.53	82.29
Price / Book	3.52	10.77	13.07	4.64
Net Income	C$3.26M	C$2.78B	C$3.45B	C$299.09M
7 Day Performance	4.94%	-0.17%	0.74%	0.92%
1 Month Performance	3.51%	0.00%	1.40%	3.90%
1 Year Performance	93.09%	161.17%	67.03%	36.15%

Medexus Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MDP Medexus Pharmaceuticals	N/A	C$5.31 -2.6%	N/A	+104.1%	C$168.12M	C$103.30M	N/A	98	Positive News
WEED Canopy Growth	2.474 of 5 stars	C$1.33 +2.3%	C$1.88 +41.0%	-37.9%	C$561.47M	C$284.60M	N/A	2,700	Earnings Report
FRX Fennec Pharmaceuticals	0.0428 of 5 stars	C$15.00 +0.8%	N/A	+36.0%	C$521.06M	C$51.00M	N/A	10	Gap Up
CPH Cipher Pharmaceuticals	1.9875 of 5 stars	C$17.75 +4.9%	C$17.00 -4.2%	-6.5%	C$450.69M	C$50.94M	14.92	5	Positive News Earnings Report
VGW Valens GroWorks	N/A	C$3.10 +1.6%	N/A	+0.0%	C$383.88M	C$27.50M	N/A	N/A

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (TSE:MDP) was last updated on 8/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Medexus Pharmaceuticals (MDP) Competitors

MDP vs. WEED, FRX, CPH, VGW, and VBV

How does Medexus Pharmaceuticals compare to Canopy Growth?

Summary

How does Medexus Pharmaceuticals compare to Fennec Pharmaceuticals?

Summary

How does Medexus Pharmaceuticals compare to Cipher Pharmaceuticals?

Summary

How does Medexus Pharmaceuticals compare to Valens GroWorks?

Summary

How does Medexus Pharmaceuticals compare to VBI Vaccines?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MDP vs. The Competition

Medexus Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Medexus Pharmaceuticals (MDP) Competitors

MDP vs. WEED, FRX, CPH, VGW, and VBV

How does Medexus Pharmaceuticals compare to Canopy Growth?

Do analysts prefer MDP or WEED?

Does the media favor MDP or WEED?

Is MDP or WEED more profitable?

Do institutionals & insiders hold more shares of MDP or WEED?

Which has higher earnings & valuation, MDP or WEED?

Which has more volatility and risk, MDP or WEED?

Summary

How does Medexus Pharmaceuticals compare to Fennec Pharmaceuticals?

Do institutionals and insiders have more ownership in FRX or MDP?

Is FRX or MDP more profitable?

Which has more volatility and risk, FRX or MDP?

Does the media refer more to FRX or MDP?

Which has stronger valuation & earnings, FRX or MDP?

Do analysts recommend FRX or MDP?

Summary

How does Medexus Pharmaceuticals compare to Cipher Pharmaceuticals?

Do institutionals & insiders have more ownership in CPH or MDP?

Which has more volatility & risk, CPH or MDP?

Is CPH or MDP more profitable?

Which has higher earnings and valuation, CPH or MDP?

Do analysts rate CPH or MDP?

Does the media refer more to CPH or MDP?

Summary

How does Medexus Pharmaceuticals compare to Valens GroWorks?

Is VGW or MDP more profitable?

Do insiders and institutionals have more ownership in VGW or MDP?

Does the media favor VGW or MDP?

Which has better earnings and valuation, VGW or MDP?

Summary

How does Medexus Pharmaceuticals compare to VBI Vaccines?

Do institutionals and insiders have more ownership in VBV or MDP?

Which has higher valuation and earnings, VBV or MDP?

Is VBV or MDP more profitable?

Does the media refer more to VBV or MDP?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MDP vs. The Competition

Medexus Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools